EIKN
Eikon Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.70
+3.77%Oct 18, 2026, 22:05 UTC
Eikon Therapeutics, Inc. announced that seven abstracts covering its clinical candidates were published for presentation at the 2026 ESMO Congress beginning October 23 in Madrid.
Source:Oct 15, 2026, 12:00 UTC
Eikon Therapeutics, Inc. submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate EIK1006 for advanced metastatic prostate cancer.
Source:Aug 13, 2026, 20:02 UTC
Eikon Therapeutics reported its financial results for the second quarter of 2026 and provided clinical program updates on August 13, 2026.
Source:Jul 27, 2026, 11:30 UTC
Eikon Therapeutics dosed the first patient in a Phase 2/3 trial of EIK1001 for non-small cell lung cancer.
Source:Jun 10, 2026, 00:00 UTC
Ma. Fatima D. Francisco was appointed as a Class I director and member of the Compensation Committee of Eikon Therapeutics, Inc., effective June 15, 2026, with an option to purchase 85,937 shares of common stock at $8.96 per share vesting in 48 equal monthly installments.